Al-Ola Abdallah and Shebli Atrash
Aug 9, 2025, 11:59
Al-Ola Abdallah: MRD Negativity Isn’t the Finish Line
Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on LinkedIn:
“In an interview with Cancer Network, Vice of USMIRC Shebli Atrash, MD, MS, FACP discussed his presentation on T-cell engagers in multiple myeloma that he gave at the 2025 National Immune Cell Effector Therapy ICE_T Conference.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.”
More posts featuring Al-Ola A Abdallah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 9, 2025, 11:59
Aug 9, 2025, 11:37
Aug 9, 2025, 11:29
Aug 9, 2025, 11:12
Aug 9, 2025, 10:59
Aug 9, 2025, 10:52
Aug 9, 2025, 10:47